Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a study titled ‘A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma.’ The study aims to evaluate the safety and effectiveness of etentamig, an investigational drug, in combination with other anti-cancer treatments for adults with relapsed or refractory multiple myeloma. This research is significant as it explores new therapeutic options for a challenging condition.
The study tests etentamig, administered intravenously, alongside other treatments such as pomalidomide, lenalidomide, and daratumumab. These combinations aim to enhance treatment efficacy for multiple myeloma patients.
The study is designed as an interventional trial with a non-randomized, parallel assignment model. There is no masking involved, and the primary purpose is treatment. The study is currently in Phase 1, focusing on dose escalation and expansion to determine the optimal dosing strategy.
The study began on February 18, 2022, with an estimated primary completion date yet to be announced. The latest update was submitted on August 22, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
This update could positively influence AbbVie’s stock performance by demonstrating progress in their oncology pipeline, potentially boosting investor confidence. The study’s results may also impact the competitive landscape in the multiple myeloma treatment market, where several pharmaceutical companies are vying for breakthroughs.
The study is ongoing, with further details available on the ClinicalTrials portal.